NCT02455024View on ClinicalTrials.gov

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

March 2, 2018

Primary Completion Date

February 19, 2019

Study Completion Date

February 19, 2019

Conditions
Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
Trial Locations (2)

10532

Hudson Valley Hematology Oncology Associates (Site 236), Hawthorne

07601

John Theurer Cancer Center at Hackensack UMC (Site 128), Hackensack

Sponsors
All Listed Sponsors
collaborator

United BioSource, LLC

INDUSTRY

lead

Ariad Pharmaceuticals

INDUSTRY